| "ECONOMIC AND OUTCOMES ISSUES IN MENTAL HEALTH"
THE ECONOMIC BURDEN OF ALZHEIMER'S DISEASE TO MEDICAID IN CALIFORNIA
("MEDI-CAL") Menzin J, Lang K, Friedman M, Neumann P, Boston Health Economics, Inc., Billerica, MA,
Harvard School of Public Health, MA USA
COST IMPACT OF USING OLANZAPINE AT A VETERANS AFFAIRS MEDICAL CENTER
Weiss MA, McCollum M. Department of Veterans Affairs Medical Center, Denver CO, USA
COMPARISON OF SUMATRIPTAN (IMITREX®) AND OVER-THE-COUNTER (OTC) MEDICATION
USE ACCORDING TO MIGRAINE SEVERITY
Yuran TE1, Schaffer M1, Lofland
JH1, Johnson NE1, Johnson
KA2, 1Thomas Jefferson
University, Philadelphia, PA, USA 2HealthAmerica of Pennsylvania Inc., Pittsburgh, PA, USA
SSRI ANTIDEPRESSANT USE PATTERNS AND THEIR RELATION TO CLINICAL GLOBAL
IMPRESSIONS SCORES: A NATURALISTIC STUDY
Hylan TR1, Meneades L1, Crown
WH3, Sacristan1, JA, Gilaberte
I3, Montejo AL2,
1Eli Lilly and Company, Indianapolis, IN USA;
2Hospital Universitario, Salamanca, Spain;
3The MEDSTAT Group, Cambridge, MA USA.
SSRI ANTIDEPRESSANT USE IN PRIMARY CARE IN THE UNITED KINGDOM: A MULTIVARIATE ANALYSIS
Hylan TR1, Donoghue JM2, Dunn
RL3, Ozminkowski RJ3.
1Eli Lilly and Company, Indianapolis, IN
USA; 2Wirral Hospital, Merseyside, UK;
3The MEDSTAT Group, Ann Arbor, MI, USA.
EVALUATION OF ANTIDEPRESSANT UTILIZATION PATTERNS AND ASSOCIATED DEPRESSION
DIAGNOSES AMONG PATIENTS IN A NATIONAL MANAGED CARE ORGANIZATION
Way K1, Brintnall EO2, Whitehouse
DJ2, Young CH1, Gregor
KJ1, Hughes T1, 1PCS Health
Systems, Inc., Scottsdale, AZ. 2HCC Behavioral Care, Eden Praire, MN, USA
"ECONOMIC AND OUTCOMES ISSUES IN CARDIOVASCULAR DISEASE"
ECONOMIC OUTCOMES OF CAROTID ENDARTERECTOMY FOR STROKE
Patterson HK1 and Seltzer J2,
1SmithKline Beecham Pharmaceuticals, Collegeville, PA, USA,
2Premier Research Worldwide, Philadelphia, PA, USA
COST-EFFECTIVENESS AND ECONOMIC EFFICIENCY: THE CASE OF STATIN THERAPY IN
SECONDARY PREVENTION OF CORONARY HEART DISEASE
Russell MW, Huse DM, Miller JD, Hartz SC, Medical Research International, Burlington, MA, USA
ADHERENCE TO HYPERTENSION THERAPY: THE EFFECT OF INITIAL DRUG CHOICE
Caro JJ1, Speckman JL1, Salas
M1, Raggio G1, Jackson
JD2. 1Caro Research, Boston, MA,
2Bristol-Myers Squibb, Princeton, NJ, USA
COST-EFFECTIVENESS OF A PHARMACOLOGICAL APPROACH TO RESTENOSIS PROPHYLAXIS
Schömig A1, Schwicker
D2, Darcis T3, Banz
K4, Serruys PW5.
1Universität München, München,
Germany; 2Parpexel International, Alexandria VA, USA;
3UCB Pharm SA, Belgium; 4Health Econ Ltd.Basle,
Switzerland; 5University Rotterdam, Rotterdam, The Netherlands
EFFECT OF COMPLIANCE ON HEALTH AND ECONOMIC OUTCOMES: ROLE OF
CONJUGATED ESTROGEN ON DEPRESSION AND CARDIOVASCULAR DISORDERS.
Heaton AH1, Flinner A1, Martin
SL1, Emmett KE2, Buatti
MC2; 1Pharmacy Gold, Eagan, MN, USA;
2Wyeth-Ayerst Laboratories, Philadelphia, PA, USA
CONFOUNDING BY INDICATION IN CALCIUM CHANNEL BLOCKER TREATMENT OF
HYPERTENSION OR ANGINA
Mallick R1, Leader S1, Roht
L2, 1Pracon, Reston, VA, USA;
2Hoechst Marion Roussel, Kansas City, MO, USA
|